Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Liabilities (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Total Liabilities for 16 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 16.96% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 16.96% year-over-year, with the annual reading at $7.3 million for FY2025, 16.96% up from the prior year.
  • Total Liabilities hit $7.3 million in Q4 2025 for Guided Therapeutics, up from $6.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $10.3 million in Q1 2021 to a low of $5.5 million in Q4 2023.
  • Historically, Total Liabilities has averaged $6.6 million across 5 years, with a median of $6.3 million in 2024.
  • Biggest five-year swings in Total Liabilities: crashed 57.44% in 2021 and later rose 16.96% in 2025.
  • Year by year, Total Liabilities stood at $7.5 million in 2021, then decreased by 16.51% to $6.2 million in 2022, then dropped by 12.39% to $5.5 million in 2023, then rose by 14.47% to $6.3 million in 2024, then grew by 16.96% to $7.3 million in 2025.
  • Business Quant data shows Total Liabilities for GTHP at $7.3 million in Q4 2025, $6.5 million in Q3 2025, and $6.4 million in Q2 2025.